Interim results on the use of dendritic cells in glioblastoma by Dr. Marnix Bosch

At the world-renowned 2018 Annual Meeting of the American Society of Clinical Oncology (ASCO), Dr. Marnix Bosch presented interim results from a Phase III study on the use of a dendritic cell vaccine (DCVax®) in glioblastoma. This is the most common type of brain tumor and has a very poor prognosis.

This multicenter double-blind study investigated the effect of DC vaccination in addition to standard therapy with surgery and radiochemotherapy in 331 selected patients. Patients were included immediately after initial diagnosis, provided they had a Karnofsky index ≥ 70, for example. Patients with certain comorbidities, advanced tumor stage, or recurrence were not included. The interim results show that the vaccination is very well tolerated and leads to an extension of survival time compared to standard therapy.

The results of the study are consistent with the clinical experience gained from individual treatment trials conducted by the IOZK using our DC vaccine in combination with oncolytic viruses.

• First results on survival from a large Phase 3 clinical trial of an autologous dendritic cell vaccine in newly diagnosed glioblastoma.